title: Secondary acute nonlymphocytic leukemia following successful chemotherapy combining cisplatin, doxorubicin, and cyclophosphamide for stage IV epithelial ovarian cancer.
abstract: Although chemotherapy is indispensable for the treatment of ovarian cancer, secondary acute leukemia has become increasingly important as one of the most unfavorable late effects according to widespread long-term chemotherapy. We report a patient suffering from acute nonlymphocytic leukemia (ANLL) 3 years after treatment for stage IV ovarian cancer began.
authors.affiliation: Department of Obstetrics and Gynecology, Hirosaki University School of Medicine, Aomori, Japan. yokoyama@cc.hirosaki-u.ac.jp
authors.forename: Y
authors.initials: Y
authors.lastname: Yokoyama
authors.forename: M
authors.initials: M
authors.lastname: Futagami
authors.forename: Y
authors.initials: Y
authors.lastname: Fukushi
authors.forename: T
authors.initials: T
authors.lastname: Sakamoto
authors.forename: T
authors.initials: T
authors.lastname: Higuchi
authors.forename: S
authors.initials: S
authors.lastname: Fujii
authors.forename: S
authors.initials: S
authors.lastname: Sato
authors.forename: H
authors.initials: H
authors.lastname: Takami
authors.forename: Y
authors.initials: Y
authors.lastname: Saito
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001706:Biopsy; D001853:Bone Marrow / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D018282:Cystadenocarcinoma, Mucinous / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008875:Middle Aged; D008942:Mitoxantrone / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D011239:Prednisolone / Q000627:therapeutic use; D012074:Remission Induction / Q000379:methods; D012086:Reoperation
chemical_list: D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D018906:Antineoplastic Agents, Alkylating; D003561:Cytarabine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D008942:Mitoxantrone; D002945:Cisplatin; D015255:Idarubicin; D003630:Daunorubicin